Search

Search Results

• PO:07:108 | Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study Enrico Marchetta¹, Andrew Östör^2|8, Eugen Feist³, Prodromos Sidiropoulos⁴, Jérôme Avouac⁵, Martin Rebella^6|7, Rajaie Namas⁹, Erin Mcdearmon Blondell¹⁰, Ivan Lagunes¹⁰, Tianming Gao¹⁰, Tim Shaw¹⁰, Suzan Attar¹¹ | ¹AbbVie Srl Roma, Italy; ²Monash University and Emeritus Research, Melbourne, Victoria, Melbourne, Australia; ³Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Vogelsang Gommern, Germany; ⁴Faculty of Medicine, University of Crete, Heraklion, Heraklion, Greece; ⁵Service de Rhumatologie, Hôpital Cochin, AP HP Centre Université Paris Cité, Parigi, France; ⁶Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Montevideo, Uruguay; ⁷Unidad de Enfermedades Autoinmunes Sistémicas, MUCAM, Montevideo, Montevideo, Uruguay; ⁸Australian National University, Camberra, Australia; ⁹Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, United Arab Emirates; ¹⁰AbbVie Inc., North Chicago, Illinois, United States of America Chicago, USA; ¹¹King Abdulaziz University, Jeddah, Saudi Arabia

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2306

  53
• 

  Coexisting rheumatoid arthritis and sickle cell disease: case series and literature review

  Abdallah Alqethami, Sabri Alsaeedi, Samera Felemban, Abdulelah Qadi

  07-01-2025

  https://doi.org/10.4081/reumatismo.2025.1682

  2718

  PDF: 547
• 

  Rheumatology research output in the Arab World: despite the challenges

  G. El Hasbani, A.S.M. Jawad, I. Uthman

  29-12-2022

  https://doi.org/10.4081/reumatismo.2022.1520

  1286

  PDF: 699